Pharmacyclics Inc

Pharmacyclics — Technical Presentation (June 2012)

21 slides from Pharmacyclics's technical presentation, Jun 4, 2012

  1. Slide 1: A Phase Ib/II Study of BTK Inhibitor PCI-32765 and Ofatumumab in CLL/SLL

    Z a). A Phase lIb/Il Study Evaluating Activity and Tolerability of BTK Inhibitor PCI-32765 ani Ofatumumab In Patients With Chronic 4 Lymphocytic Leukemia/Small Lymphocyti Lymphoma (CLL/SLL) and related diseas Andritsos, MD Kami Maddocks, MD, Kristie Blum, MD, Michael Gre' PhD, Jennifer Woyach, MD, A

  2. Slide 2: Disclosures

    Disclosures RESEARCH FUNDING: Pharmacyclics, Inc. (trial support) EMPLOYEE: N/A STOCKHOLDER: N/A CONSULTANT: N/A SCIENTIFIC ADVISORY BOARD: N/A Nel The James GU

  3. Slide 3: Bruton's Tyrosine Kinase (BTK)

    Bruton’s Tyrosine Kinase (BTK) » Expressed and functional across non-T cell hematopoietic lineages = Lies proximally in the BCR signaling pathway = BCR signaling necessary for a number of normal B cell functions = Mouse knock out or mutation has a predominately B-cell phenotype = BCR signaling is co

  4. Slide 4: Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) | Orally bioavailable inhibitor of “| Aue | | BTIK - Abrogates protective effects of the CLL microenvironment! Has single-agent activity in = NL patients with a relapsed/refractory CLL? oe enn ORR 67% with 86% estimated 1 yr PFS Lymphocytosis frequent . after initiation, abates

  5. Slide 5: Ofatumumab

    Ofatumumab Fully humanized type | CD20 monoclonal antibody Advantages over rituximab: Greater CDC, ADCC, and apoptosis versus rituximab‘ Slower off-rate More stable CD20 binding? Has activity in patients with fludarabine and alemtuzumab-refractory (ORR 58%) and bulky fludarabine-refractory disease (

  6. Slide 6: OSU 10053

    OSU 10053 Single-institution study evaluating the safety and efficacy of the combination of ibrutinib and ofatumumab for patients with relapsed/refractory CLL/SLL and related diseases Evaluations of three dosing strategies currently underway x Ne (ilirne James

  7. Slide 7: OSU 10053: Cohort A

    OSU 10053: Cohort A Cohort A: aan mg ibrutinib alone administered daily for 28 days during cycle 1 Ofatumumab added at 300 mg on day 1 of cycle 2, followed by 2000 mg on days 8, 15, and 22 of cycle 2, days 1, 8, 15, and 22 of cycle 3, then on day 1 of cycles 5-8 (follows package insert) Objectives:

  8. Slide 8: OSU 10053: Cohort A

    OSU 10053: Cohort A Based on data entered into the Pharmacyclics study database by investigators as of March 13, 2012 Safety evaluation: Six patients initially treated through 2 cycles Regimen considered sufficiently tolerable if at most one patient experienced a DLT Efficacy evaluation: Minimax Sim

  9. Slide 9: Patient Eligibility

    Patient Eligibility Histologically confirmed CLL/SLL, prolymphocytic leukemia, or Richter’s transformation with an indication for treatment per IWCLL guidelines 22 prior therapies, including a purine nucleoside analog >10% CD20 expression on CLL cells* Adequate end-organ function ANC 2 1000/uL in th

  10. Slide 10: Patient Characteristics

    Patient Characteristics ‘Age, years Diagnosis, #%) ECOG PS, #(%) Prior Rx mRai Staging, #(%) Median: Range: 270 years, # (%) CLL SLL PLL Richter's 0 1 Median: Range: 2 3regimens: Low Risk Intermediate Risk High Risk 51-85 12 (44) 22(81) 1(4) 1(4) 3(11) 10 (37) 17 (63) 8 2-10 16 (59) 1(4) 13 (48) 13

  11. Slide 11: Patient Characteristics (cont.)

    Patient Characteristics (cont.) 7) (%) Purine Analog Refractory, #(%) 11 (41) Cytopenia at baseline, # (%) ANC < 1500/yL 4(15) HGB < 11g/dL 9(33) Platelets < 100,000/uL 9 (33) HGB < 11g/dL or PLT < 100,000 pL 13 (48) Prognostic Markers, # (%). IgVH unmutated: 20/22 (91) Del(17p): 10 (37) Del(11q): 9

  12. Slide 12: Patient Disposition

    Patient Disposition Follow-Up Median (months) 9.8 Range §.2-12.9 Patients Still on Study, # (%) 24 (89) Patients Discontinued, # (%) 3(11) Primary Reasons for Discontinuation, # (%) Went to Transplant 1(4) Disease Progression 1 (4) Death 1(4)

  13. Slide 13: Adverse Events Occurring in >20% of Patients

    nl Respiratory infection =i Stomatitis —_ = Rash Peripheral sensory neuropathy Fatigue Diarrhea Adverse Events Occurring in >20% of Patients Grade 1 @ Grade 2 Grade 3 @Grade 4

  14. Slide 14: Grade Infectious Complications

    Grade 3 Infectious Complications Urinary Tract Infection Pneumonia Enterocolitis Cellulitis Bacteremia

  15. Slide 15: Best Response

    Best Response CLU/SLLIPLL Richter’s (N=24) (N=3) #(%) #(%) CR 1 (4%) 0 PR 23 (96%) 2 (67%)

  16. Slide 16: Mean Percent Change From Baseline

    Mean Percent Change From Baseline Ibrutinib Mediates Transient Rise in Lymphocyte Count that is Diminished in Combination with ofatumumab Blood Lymphocytes Lymph Nodes — ALcbrutinib single agent ALC Ibrutinib = ofatumumab 100 — sP0—Ibrutinib single agent — 5PD=Ibrutinib ~ ofatumumab Screen oyelet cy

  17. Slide 17: Bone Marrow Response

    . Bone Marrow Response | _ Screening E |

  18. Slide 18: Sustained Improvement Among Patients with Pretreatment Cytopenias

    Sustained Improvement* Among Patients with Pretreatment Cytopenias % with sustained improvement ANC (n=4) Hemoglobin (n=9) Platelets (n=9) ie) 10 20 30 40 50 60 70 80 “Sustained improvement is defined as improvement in cytopenia by >50%, or Hgb >11 g/dL, ANC > 1500 cells/iL, or pits >100,000 lasting

  19. Slide 19: Progression-free survival (CLL/SLL/PLL)

    Progression-free survival (CLL/SLL/PLL) PFS Kaplan-Meier Curve 104 os os o74 os4 os4 o44 os4 024 oa oo 1: CLUSLUPLL (N=24) Aarisk| 24 24 24 24 23 PFS Probability ae + Censored ° ° 2 4 6 8 Months on Study 10 12 14 Richter’s patients: 2/3 eventually progressed at 4.7 and 5.6 months; the third was cens

  20. Slide 20: Conclusions

    Conclusions Ibrutinib in combination with ofatumumab is well- tolerated and highly active in patients with relapsed/refractory CLL/SLL/PLL Among patients with CLL/SLL/PLL, the combination resulted in a 100% ORR irrespective of genomics There was a rapid onset of response, favorable safety profile, a

  21. Slide 21: Acknowledgements

    Acknowledgements The patients who participate in clinical trials and their families! CLL Team at OSU John Byrd, MD Michael Grever, MD Jeffrey Jones, MD, MPH Joseph Flynn, DO, MPH Leslie Andritsos, MD Kami Maddocks, MD Jennifer Woyach, MD CLLLab Amy Johnson, PhD Raj Muthusamy, DVM, PhD Erin Hertlein,

Pharmacyclics — Technical Presentation (June 2012) on 6ix